Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1279897

Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease


Grubić Rotkvić, Petra; Ćelap, Ivana; Bralić Lang, Valerija; Jug, Juraj; Snagić, Andrea; Huljev Šipoš, Ivana; Cigrovski Berković, Maja
Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease // Journal of diabetes and its complications, 37 (2023), 8; 108541, 10 doi:10.1016/j.jdiacomp.2023.108541 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1279897 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease

Autori
Grubić Rotkvić, Petra ; Ćelap, Ivana ; Bralić Lang, Valerija ; Jug, Juraj ; Snagić, Andrea ; Huljev Šipoš, Ivana ; Cigrovski Berković, Maja

Izvornik
Journal of diabetes and its complications (1056-8727) 37 (2023), 8; 108541, 10

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
diabetes mellitus type 2 ; cardiovascular complications ; diabetic cardiomyopathy ; SGLT2 inhibitors

Sažetak
This prospective observational study evaluated the possible mechanisms of action of SGLT2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) without overt heart disease. The study was designed to verify whether SGLT2i impact biomarkers of: myocardial stress–NT-proBNP, inflammation–high sensitivity C-reactive protein, oxidative stress –myeloperoxidase, functional and structural echocardiographic parameters, in patients with T2DM on metformin (heart failure stages A and B) who needed treatment intensification with a second antidiabetic agent. The patients were divided in two groups – the ones planned to receive SGLT2i or DPP-4 inhibitor (except saxagliptin). At baseline, and after six months of therapy, 64 patients underwent blood analysis, physical and echocardiography examination. There were no significant differences between the two groups in terms of biomarkers of myocyte and oxidative stress, inflammation and blood pressure. Body mass index, triglycerides, aspartate aminotransferase, uric acid, E/E′, deceleration time and systolic pressure in the pulmonary artery significantly decreased, while stroke volume, indexed stroke volume, high-density lipoprotein, hematocrit and hemoglobin significantly increased in the group on SGLT2i. According to the results, SGLT2i mechanisms of action comprise rapid changes in body composition and metabolic parameters, reduced cardiac load and improvement in diastolic and systolic parameters.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Kineziološki fakultet, Zagreb,
KBC "Sestre Milosrdnice",
Klinički bolnički centar Zagreb

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Grubić Rotkvić, Petra; Ćelap, Ivana; Bralić Lang, Valerija; Jug, Juraj; Snagić, Andrea; Huljev Šipoš, Ivana; Cigrovski Berković, Maja
Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease // Journal of diabetes and its complications, 37 (2023), 8; 108541, 10 doi:10.1016/j.jdiacomp.2023.108541 (međunarodna recenzija, članak, znanstveni)
Grubić Rotkvić, P., Ćelap, I., Bralić Lang, V., Jug, J., Snagić, A., Huljev Šipoš, I. & Cigrovski Berković, M. (2023) Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease. Journal of diabetes and its complications, 37 (8), 108541, 10 doi:10.1016/j.jdiacomp.2023.108541.
@article{article, author = {Grubi\'{c} Rotkvi\'{c}, Petra and \'{C}elap, Ivana and Brali\'{c} Lang, Valerija and Jug, Juraj and Snagi\'{c}, Andrea and Huljev \v{S}ipo\v{s}, Ivana and Cigrovski Berkovi\'{c}, Maja}, year = {2023}, pages = {10}, DOI = {10.1016/j.jdiacomp.2023.108541}, chapter = {108541}, keywords = {diabetes mellitus type 2, cardiovascular complications, diabetic cardiomyopathy, SGLT2 inhibitors}, journal = {Journal of diabetes and its complications}, doi = {10.1016/j.jdiacomp.2023.108541}, volume = {37}, number = {8}, issn = {1056-8727}, title = {Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease}, keyword = {diabetes mellitus type 2, cardiovascular complications, diabetic cardiomyopathy, SGLT2 inhibitors}, chapternumber = {108541} }
@article{article, author = {Grubi\'{c} Rotkvi\'{c}, Petra and \'{C}elap, Ivana and Brali\'{c} Lang, Valerija and Jug, Juraj and Snagi\'{c}, Andrea and Huljev \v{S}ipo\v{s}, Ivana and Cigrovski Berkovi\'{c}, Maja}, year = {2023}, pages = {10}, DOI = {10.1016/j.jdiacomp.2023.108541}, chapter = {108541}, keywords = {diabetes mellitus type 2, cardiovascular complications, diabetic cardiomyopathy, SGLT2 inhibitors}, journal = {Journal of diabetes and its complications}, doi = {10.1016/j.jdiacomp.2023.108541}, volume = {37}, number = {8}, issn = {1056-8727}, title = {Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease}, keyword = {diabetes mellitus type 2, cardiovascular complications, diabetic cardiomyopathy, SGLT2 inhibitors}, chapternumber = {108541} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font